?:abstract
|
-
Allergic diseases affect one third of general population and usually require regular application of anti-allergic treatment of allergen immuno-therapy Allergic people and patients with chronic allergic respiratory diseases, based on the published studies and case report series, do not yield an increased risk for obtaining COVID-19 compared to the general population Anti-allergic medicaments /with the exception of systemic corticosteroids) do not represent a risk in relation with COVID-19 and its complicated course Patients should continue in their chronic anti-allergic treatment (including biologicals, immunosuppressants, and corticosteroids) without the withdrawal or tapering the dose Patients should continue also in the applied allergen immunotherapy In case of acquiring COVID-19, it is necessary to contact the caring specialists with the highly-individualized re-assessment of the therapeutic strategy The aim is to maintain the achieved control over allergic disease
|